Yang Ming-Wei, Chen Feng, Zhu Ding-Jun, Li Jia-Zhu, Zhu Jin-Ling, Zeng Wei, Qu Shi-Lin, Zhang Yun
Jingmen 2nd People's Hospital of Hubei Province Jingmen 448000, China.
Jingzhou Hospital of Infectious Disease (Chest Hospital) of Hubei Province Jingzhou 434000, China.
Zhongguo Zhong Yao Za Zhi. 2020 May;45(10):2221-2231. doi: 10.19540/j.cnki.cjcmm.20200323.501.
In this paper, we analyzed medical records of 40 patients with coronavirus disease 2019(COVID-19), in order to explore the clinical efficacy of Matrine and Sodium Chloride Injection in the treatment of COVID-19. The investigation was based on the results of a previous animal test, which was aimed to investigate and confirme the clinical efficacy of Matrine and Sodium Chloride Injection in the treatment of COVID-19. The animal test demonstrated that Matrine and Sodium Chloride Injection has a significant therapeutic effect on the human coronavirus pneumonia for the model mice. The lung inhibition index reached up to 86.86%. The evaluation was conducted on 40 confirmed cases of COVID-19 treated at Jingzhou Hospital of Infectious Disease(Chest Hospital) of Hubei Pro-vince from January 30(th) to March 21(th), 2020. In these cases, patients were treated with other integrated Chinese and Western medicines regimens in the recommended Matrine and Sodium Chloride Injection diagnosis and treatment regimen. The clinical manifestations, laboratory data, nucleic acid clearance time, and imaging data were compared and analyzed before and after treatment. After administration with Matrine and Sodium Chloride Injection, the clinical symptoms of 40 cases were alleviated markedly, and their blood analysis and biochemical indexes returned to normal. The lung CT showed more than 50% of lesion absorption rate, and the viral nucleic acid test showed the average clearance time of patients was 16.6 days, and the average length of hospital stay was 25.9 days. After administration with Matrine and Sodium Chloride Injection, the symptoms of cough and fatigue were alleviated significantly, and the appetite was significantly improved compared with before, especially for patients with gastrointestinal symptoms. Additionally, laboratory indicators, especially absolute value and ratio of lymphocytes and CRP were significantly alleviated. According to the chest CT for short-term review, the absorption of lung lesions was faster than before, especially for grid-like and fibrotic lesions. Compared with antiviral drugs, such as Abidol and Kriging, the nucleic acid clearance time was significantly shorter than the cases treated with Matrine and Sodium Chloride Injection. The clinical effective rate of 40 cases was 100.0%. We believed that Matrine and Sodium Chloride Injection have a good clinical effect in the treatment of COVID-19, and suggested increasing the clinical application and further conducting large-sample-size cli-nical verification.
在本文中，我们分析了40例2019冠状病毒病（COVID-19）患者的病历，以探讨苦参碱氯化钠注射液治疗COVID-19的临床疗效。该研究基于先前的动物试验结果，旨在研究并确认苦参碱氯化钠注射液治疗COVID-19的临床疗效。动物试验表明，苦参碱氯化钠注射液对模型小鼠的人冠状病毒肺炎有显著治疗作用。肺抑制指数高达86.86%。对2020年1月30日至3月21日在湖北省荆州市传染病医院（胸科医院）治疗的40例确诊COVID-19病例进行了评估。在这些病例中，患者在推荐的苦参碱氯化钠注射液诊断和治疗方案基础上，接受了其他中西医结合治疗方案。对治疗前后的临床表现、实验室数据、核酸清除时间和影像学数据进行了比较和分析。使用苦参碱氯化钠注射液后，40例患者的临床症状明显缓解，血液分析和生化指标恢复正常。肺部CT显示病变吸收率超过50%，病毒核酸检测显示患者平均清除时间为16.6天，平均住院时间为25.9天。使用苦参碱氯化钠注射液后，咳嗽和乏力症状明显缓解，食欲较之前显著改善，尤其是有胃肠道症状的患者。此外，实验室指标，尤其是淋巴细胞绝对值和比例以及CRP显著改善。根据短期胸部CT复查，肺部病变吸收比之前更快，尤其是网格状和纤维化病变。与阿比多尔和克力芝等抗病毒药物相比，使用苦参碱氯化钠注射液治疗的病例核酸清除时间明显更短。40例患者的临床有效率为100.0%。我们认为苦参碱氯化钠注射液治疗COVID-19具有良好的临床效果，并建议增加临床应用并进一步进行大样本临床验证。
